-
Endpoints News2 weeks ago
Lessons from the last health tech revolution
Given his former role as US national coordinator for health IT, you might expect that Farzad Mostashari would be an AI enthusiast. But his experience overseeing...
-
Endpoints News2 weeks ago
FDA warns ImmunityBio over misleading podcast with Patrick Soon-Shiong
The FDA warned California-based ImmunityBio for a TV advertisement and podcast that gave the “misleading impression” that Anktiva, the company’s treatment for a type of bladder...
-
Endpoints News2 weeks ago
Karyopharm’s mixed myelofibrosis data; Rezolute to seek FDA approval despite trial failure
Plus, news about Aardvark Therapeutics, RA Capital, Gilead and EpiFrontier: 📊 Karyopharm’s late-phase myelofibrosis data: The company’s drug selinexor achieved one co-primary endpoint but missed on...
-
Endpoints News2 weeks ago
Q&A: Controversial embryo editing entrepreneur Cathy Tie on her new startup
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening...
-
Endpoints News2 weeks ago
XO Health to expand its alternative health plan nationwide
XO Health, a startup offering an alternative health plan, is gearing up to work with self-insured employers and plan administrators nationwide. The startup is expanding its...
-
Endpoints News2 weeks ago
Triangle Health raises $4M as people turn to AI to understand their health
Triangle Health raised $4 million to help people understand their health conditions and explore treatment options, Endpoints News learned exclusively. After a person uploads their health...
-
Endpoints News2 weeks ago
Biotech investors set to meet with key congressional panel
A group of biotech investors will meet with members of a congressional commission that’s been charged with keeping the US competitive in biotech and protecting national...
-
Endpoints News2 weeks ago
Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfront
Shionogi is doubling down on its sleep disorder pipeline by buying out Apnimed’s half of their joint venture in the niche field. The Japanese pharma will...
-
Endpoints News2 weeks ago
Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in
Gilead Sciences is set to enter the T cell engager space in an unusual — perhaps even unprecedented — deal arrangement that involves the pharma budgeting...
-
Endpoints News2 weeks ago
Merck partners with Flagship startup Quotient to search for genetic clues to IBD
Quotient Therapeutics, a startup studying how tiny genetic typos cause some cells to get sick but allow others to remain healthy, has struck a partnership with...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
